Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Assets: 2009-2025

Historic Assets for Corcept Therapeutics (CORT) over the last 13 years, with Sep 2025 value amounting to $823.6 million.

  • Corcept Therapeutics' Assets rose 5.02% to $823.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $823.6 million, marking a year-over-year increase of 5.02%. This contributed to the annual value of $840.6 million for FY2024, which is 35.24% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Assets stood at $823.6 million, which was up 2.73% from $801.7 million recorded in Q2 2025.
  • Corcept Therapeutics' 5-year Assets high stood at $846.5 million for Q1 2025, and its period low was $423.8 million during Q4 2021.
  • Its 3-year average for Assets is $711.4 million, with a median of $714.6 million in 2024.
  • In the last 5 years, Corcept Therapeutics' Assets decreased by 25.88% in 2021 and then spiked by 37.68% in 2022.
  • Corcept Therapeutics' Assets (Quarterly) stood at $423.8 million in 2021, then surged by 37.68% to $583.4 million in 2022, then increased by 6.53% to $621.5 million in 2023, then surged by 35.24% to $840.6 million in 2024, then rose by 5.02% to $823.6 million in 2025.
  • Its Assets stands at $823.6 million for Q3 2025, versus $801.7 million for Q2 2025 and $846.5 million for Q1 2025.